Raab Stephen S, Grzybicki Dana Marie, Vrbin Colleen M, Geisinger Kim R
Departments of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
Am J Clin Pathol. 2007 Jun;127(6):946-53. doi: 10.1309/XUVXFXMFPL7TELCE.
Although urine cytology is used for the early detection and surveillance of urothelial carcinoma, there has been little study of the frequency, causes, and outcomes of cytologic-histologic discrepancies. We obtained histologic follow-up in 361 (6.2%) of 5,785 voided, 124 (19.5%) of 636 lower tract instrumented, and 23 (33%) of 69 upper tract urinary cytologic specimens from 1 institution during a 2-year timeframe to determine diagnostic discrepancy frequency and outcomes. Cytologic-histologic discrepancies were observed in 208 (40.9%) cases with histologic followup, and the cause of discrepancy was interpretation and sampling in 35.1% and 63.0%, respectively. Of all discrepancies, 101 (48.6%) resulted in minimal or mild harm, consisting mainly of repeated testing and/or diagnostic delays. Severe harm never was observed. We conclude that current screening and surveillance methods that incorporate urine cytology are accurate in diagnosing urothelial cancer. However, the current protocols result in potentially reducible errors that lead to unnecessary testing and diagnostic delays.
尽管尿细胞学检查用于尿路上皮癌的早期检测和监测,但关于细胞学与组织学差异的频率、原因及结果的研究却很少。在两年时间内,我们从一家机构获取了5785份排尿尿液细胞学标本中的361份(6.2%)、636份下尿路器械检查标本中的124份(19.5%)以及69份上尿路尿液细胞学标本中的23份(33%)的组织学随访结果,以确定诊断差异的频率和结果。在有组织学随访的208例(40.9%)病例中观察到细胞学与组织学差异,差异原因分别为解读和采样的占35.1%和63.0%。在所有差异中,101例(48.6%)造成了极小或轻度伤害,主要包括重复检测和/或诊断延迟。未观察到严重伤害。我们得出结论,当前结合尿细胞学检查的筛查和监测方法在诊断尿路上皮癌方面是准确的。然而,当前方案导致了可能减少的误差,从而引发不必要的检测和诊断延迟。